HCPCS Code J9332: Injection, efgartigimod alfa-fcab, 2 mg

Key Takeaways

HCPCS Code J9332 describes injection of efgartigimod alfa-fcab, 2 mg (brand name Vyvgart), an FDA-approved IV treatment for generalized myasthenia gravis (gMG).

Medicare Part B reimburses J9332 at ASP plus 6%, updated quarterly by CMS. Rates vary by billing setting (hospital outpatient vs physician office).

Use modifier JW to report discarded drug waste and modifier JZ when there is zero waste. Conflating J9332 with J9334 (Vyvgart Hytrulo, subcutaneous) is a critical billing error.

Pabau’s claims management software supports accurate HCPCS J-code tracking, modifier documentation, and billing workflow automation for infusion practices.

HCPCS Code J9332 reports injection of efgartigimod alfa-fcab, 2 mg (brand name Vyvgart), administered intravenously. It applies exclusively to the IV formulation. The subcutaneous version, Vyvgart Hytrulo, carries a separate code, J9334, and conflating the two creates claim denials that are slow to correct.

This guide covers the code description, Medicare fee schedule methodology, applicable modifiers, ICD-10 diagnosis crosswalk, billing guidelines, and related codes for J9332.

HCPCS Code J9332: quick reference

The table below shows the canonical code data for J9332, drawn from the CMS HCPCS Level II coding system. Billers should confirm effective dates annually, as CMS updates the HCPCS code file each January.

What is efgartigimod alfa-fcab (Vyvgart)?

Efgartigimod alfa-fcab is a human IgG1 antibody fragment developed by argenx to treat generalized myasthenia gravis (gMG). The FDA approved Vyvgart in December 2021, making it the first approved FcRn blocker for gMG. It works by reducing circulating IgG antibodies, including the pathogenic acetylcholine receptor antibodies responsible for the muscle weakness characteristic of gMG.

Billing teams encounter two distinct products from argenx, each with its own HCPCS code. J9332 covers the original IV formulation (Vyvgart), administered as a one-hour infusion. J9334 covers Vyvgart Hytrulo, the subcutaneous formulation that combines efgartigimod alfa with hyaluronidase-qvfc.

These are not interchangeable codes. Submitting J9332 for a subcutaneous administration, or J9334 for an IV infusion, constitutes a billing error and typically results in a denial.

• Approved indication: generalized myasthenia gravis (gMG) in adult patients, across all antibody serotypes (AChR-positive, MuSK-positive, LRP4-positive, and seronegative), following the FDA’s May 2026 label expansion
• Route of administration (J9332): intravenous infusion over approximately 1 hour
• Dosing cycle: 10 mg/kg IV once weekly for 4 weeks; cycles repeat based on clinical response
• Manufacturer: argenx (publishes a dedicated billing and coding guide at vyvgarthcp.com)
• Subcutaneous variant: Vyvgart Hytrulo, billed separately under J9334, not J9332

Medicare fee schedule and reimbursement rates for J9332

Medicare Part B covers J9332 as a separately payable drug benefit under the ASP (Average Sales Price) methodology. CMS updates ASP-based payment rates every quarter, so the figures in the table below are representative and should always be confirmed against the current CMS Physician Fee Schedule lookup tool or the quarterly ASP Drug Pricing File before billing.

The standard Medicare payment formula is ASP plus 6%. The 6% add-on covers the cost of acquiring and storing the drug. This formula applies in both the physician office and hospital outpatient settings, though the base ASP figure and cost-sharing structures differ between settings.

Payment by billing setting: hospital outpatient vs physician office

Where a patient receives their infusion matters for reimbursement. Hospital outpatient departments (HOPDs) bill under the Outpatient Prospective Payment System (OPPS), which incorporates different fee schedule rates and cost-sharing rules compared to the physician office setting. The table below outlines the key differences.

Practices using claims management software that integrates fee schedule data can reduce the manual burden of tracking quarterly ASP updates. Reconciling rates against the quarterly CMS file is the most reliable way to avoid underbilling or overbilling on J9332 claims.

Applicable modifiers for J9332

Two modifiers are central to accurate J9332 billing: JW and JZ. CMS policy requires one of these on every single-dose vial drug claim. Omitting them entirely creates an edit that many Medicare Administrative Contractors (MACs) will reject.

CMS introduced JZ modifier reporting on single-dose vial drugs as optional starting January 1, 2023, then made it mandatory from July 1, 2023. MACs began editing and rejecting claims that omitted the JW or JZ modifier from October 1, 2023 onward. The policy applies to J9332 because Vyvgart is supplied as a single-dose vial.

Verify the current requirements against the AAPC HCPCS code lookup or the applicable MAC’s LCD for the most current guidance, as modifier policy can update independently of the annual HCPCS code file.

Beyond JW and JZ, commercial payers may require additional modifiers (such as modifier 59 for distinct procedural services, or payer-specific modifiers). Always check individual payer policies before submitting. Good EHR integration for billing workflows can flag modifier requirements automatically based on payer rules stored in the system.

ICD-10 diagnosis codes used with J9332

Linking J9332 to the correct ICD-10 diagnosis code is a medical necessity requirement. Medicare and most commercial payers will deny the claim if the diagnosis code submitted does not support the use of efgartigimod alfa-fcab.

The two primary codes are both myasthenia gravis codes within the G70 category, and the distinction between them matters. Neurologists coding other cranial nerve conditions alongside gMG may also reference G53 on our diagnostic code reference pages.

For J9332 claims, the treating neurologist’s documentation should clearly state whether an exacerbation is present, the same specificity payers expect for other muscle disorder diagnoses, such as M60.9. Payers may audit this distinction closely, particularly for high-cost biologics where medical necessity review is common.

Some payer Local Coverage Determinations (LCDs) may specify additional diagnosis codes required for coverage. Always check the applicable MAC’s LCD for gMG biologics before submitting, and verify coverage against the individual patient’s plan when billing commercial payers or Medicare Advantage.

HCPCS Code J9332 billing guidelines

Accurate J9332 billing requires matching the number of units billed to the exact dose administered. Because the code is defined per 2 mg, a standard 10 mg/kg infusion will generate multiple units depending on patient weight.

Document the prescribed dose, the actual dose administered, and any waste in the patient record before submitting the claim. Good medical forms and documentation workflows reduce the risk of unit calculation errors at the time of billing.

Units of service calculation

J9332 is billed per 2 mg. To calculate the number of units, divide the total milligrams administered by 2. Round up to the nearest whole unit for any partial unit administered.

For example, a 70 kg patient receiving a 10 mg/kg dose receives 700 mg total. That is 350 units of J9332 (700 mg divided by 2 mg per unit). Wasted drug is reported on a separate claim line with modifier JW.

Prior authorization and payer requirements

Many payers require prior authorization for J9332 before the first infusion. Requirements differ significantly across payers and plan years. Medicare fee-for-service generally does not require prior authorization for separately payable Part B drugs, but Medicare Advantage plans and commercial payers often do. Revenue cycle compliance requirements for high-cost biologics typically include:

• Confirmed diagnosis of gMG (antibody documentation may include AChR, MuSK, or LRP4 status, or note a seronegative result — a positive AChR test is no longer required for coverage)
• Documentation of prior treatment failure or contraindication to first-line therapies (acetylcholinesterase inhibitors, corticosteroids)
• Treating physician specialty and credentials (typically a board-certified neurologist)
• Treatment plan specifying intended cycle count and response assessment timeline
• Relevant lab results and functional assessment scores (e.g., MG-ADL scale) where required by payer policy

Use digital intake and prior authorization forms to capture and store the required documentation at the point of care. Keeping authorization numbers, expiration dates, and supporting clinical notes in a structured record reduces claim delays. Review documentation compliance requirements for medical offices to ensure your authorization workflow meets HIPAA standards for record retention.

Common billing errors to avoid

• Using J9334 instead of J9332: J9334 is for the subcutaneous formulation. Route of administration must match the code. IV infusion uses J9332 only.
• Missing JW/JZ modifier: CMS requires one of these on every single-dose vial drug claim. Omitting both creates a claim edit that results in rejection.
• Incorrect units: Dividing by 1 mg instead of 2 mg doubles the reported units. Always verify the per-unit denominator before submitting.
• Unsupported ICD-10 pairing: Submitting a diagnosis code outside G70.00/G70.01 (or payer-approved equivalents) without documented medical necessity typically results in a medical necessity denial.
• No prior authorization: Commercial and Medicare Advantage plans usually require PA. Submitting without a valid authorization number on file results in denial, often non-reversible without appeal.

Manage HCPCS billing with less manual work

Pabau's claims management software helps infusion and specialty practices track J-code billing, apply modifiers correctly, and reconcile Medicare fee schedule changes quarterly.

Book a demo

Related HCPCS codes

Billers working with efgartigimod products or similar neurology biologics should be familiar with the related codes below. The J9332/J9334 distinction is the most critical, but other chemotherapy J-codes in the J9000-J9999 range follow similar billing logic. Billing teams handling other neurology infusion biologics may also reference J2323, which follows a similar reimbursement structure.

For reference, you can search the full HCPCS Level II code range using the PGM Billing HCPCS lookup tool or the NLM Clinical Table Search API for programmatic lookups in billing systems.

Practices building out their injectable drug procedure codes reference library will find both resources useful for bulk code verification, alongside guides like J0640.

Streamlining J9332 billing workflows

Infusion practices billing J9332, including those running specialized IV therapy EMR software, regularly run into the same friction points: quarterly ASP reconciliation, JW modifier documentation, and prior authorization tracking across multiple payers. Each requires consistent protocols rather than ad hoc processes.

Practices that integrate their practice management software with their billing workflows can automate several of these touchpoints. Automated fee schedule syncing, modifier rule sets by payer, and structured prior authorization checklists reduce claim error rates without requiring billing staff to manually track every policy update.

For practices billing other specialty biologics, such as J3590, building these workflows early prevents audit exposure later.

Conclusion

HCPCS Code J9332 is a high-stakes code. The drug cost per cycle is significant, and payer scrutiny on biologic claims is high. The distinction between J9332 (IV) and J9334 (subcutaneous) catches billing teams off guard more often than it should.

Accurate billing comes down to three things:

• The right code for the right formulation
• The correct unit calculation per 2 mg administered
• The JW or JZ modifier on every claim

Pabau’s claims management software helps specialty and infusion practices, including those offering regenerative medicine EMR services, track these requirements, flag missing modifiers before submission, and keep pace with quarterly fee schedule updates. To see how it works in practice, book a demo with the team.

Continue your research

Billing a related neurology infusion biologic? J2323 covers Natalizumab infusions, reimbursed under the same ASP-based methodology and JW/JZ modifier rules as J9332.

Administering other J-code injectables? J3300 walks through billing a common preservative-free steroid injection.

Billing another biosimilar infusion drug? Q5114 covers billing Trastuzumab-dkst (Ogivri), reimbursed the same way as other Part B specialty biologics.

Frequently Asked Questions